Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.230
-0.010-0.11%
Volume:59.56M
Turnover:549.93M
Market Cap:106.35B
PE:23.29
High:9.320
Open:9.130
Low:9.110
Close:9.240
52wk High:11.203
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.46
T/O Rate:0.52%
Dividend:0.29
Dividend Rate:3.14%
EPS(LYR):0.396
ROE:20.90%
ROA:10.70%
PB:2.42
PE(LYR):23.29
PS:2.91

Loading ...

CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China

MT Newswires Live
·
1 hour ago

CSPC Pharma Initiates Depression Drug Candidate Trial in China

MT Newswires Live
·
1 hour ago

CSPC Pharma Launches Phase I Trial of Novel 5-HT2A Partial Agonist SYH2056 for Depression in China

Bulletin Express
·
1 hour ago

CSPC Pharma Secures Third NMPA Breakthrough Therapy Designation for EGFR-Targeting ADC SYS6010 in Recurrent/Metastatic Head-and-Neck Cancer

Bulletin Express
·
1 hour ago

CSPC Pharmaceutical - Sys6010 Granted Breakthrough Therapy Designation by Nmpa in China for R/M Hnscc

THOMSON REUTERS
·
2 hours ago

CSPC Pharma Begins Trial for Weight Management Drug in China

MT Newswires Live
·
Yesterday

CSPC Pharma Begins Phase I Trial of SYH2092, a Novel Amylin Receptor Agonist for Obesity Management

Bulletin Express
·
Yesterday

CSPC Pharma Advances Weight Management Pipeline With Phase 1 Trial Kickoff

Stock News
·
Yesterday

CSPC Pharma Wins China NMPA Clearance to Start Phase 1 Trial of Syh2092 Obesity Drug

Reuters
·
Yesterday

CSPC Pharmaceutical - Initiates Phase I Clinical Trial of Syh2092 Injection for Weight Management in China

THOMSON REUTERS
·
Yesterday

CSPC Pharmaceutical Group Stock Sheds 3.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Yesterday

Movement Alert|CSPC PHARMA Declines 3.04% in Regular Trading, Trading at HK$9.215

Market Focus
·
Yesterday

CSPC Pharma Initiates Phase II Trial of SYH2069 Dual GLP-1/GIP Agonist for Obesity Management in China

Bulletin Express
·
Aug 28

CSPC Pharmaceutical Group Stock Sheds 1.5% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 28

CSPC Pharma Gets Trial Nod for Weight Management Drug in China

MT Newswires Live
·
Aug 27

CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China

Stock News
·
Aug 27

CSPC Pharma Secures NMPA Green Light for SYH2092, a Long-Acting Amylin Receptor Agonist Targeting Obesity and Type 2 Diabetes

Bulletin Express
·
Aug 27

CSPC Wins China Clinical Trial Approval for Syh2092 Amylin Agonist Injection

Reuters
·
Aug 27

CSPC Pharmaceutical - Pharma Obtains China Clinical Trial Approval for Syh2092 Injection

THOMSON REUTERS
·
Aug 27

CSPC Pharmaceutical - Highly Potent Amylin Receptor Agonist (Syh2092 Injection) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Aug 27